Remdesivir use in the coronavirus disease 2019 pandemic: A mini-review

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative viral pathogen of coronavirus disease 2019 (COVID-19), appears to have various clinical presentations and may result in severe respiratory failure. The global SARS-CoV-2-associated viral pneumonia pandemic was first reported...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Chih-Jen, Wei, Yu-Jui, Chang, Hsu-Liang, Chang, Pi-Yu, Tsai, Chung-Chen, Chen, Yen-Hsu, Hsueh, Po-Ren
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7534785/
https://www.ncbi.nlm.nih.gov/pubmed/33060041
http://dx.doi.org/10.1016/j.jmii.2020.09.002
Descripción
Sumario:Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative viral pathogen of coronavirus disease 2019 (COVID-19), appears to have various clinical presentations and may result in severe respiratory failure. The global SARS-CoV-2-associated viral pneumonia pandemic was first reported in December 2019 in China. Based on known pharmacological mechanisms, many therapeutic drugs have been repurposed to target SARS-CoV-2. Among these drugs, remdesivir appears to be the currently most promising according to several clinical trials and reports of compassionate use. In this mini-review, we summarize the current evidence on the efficacy and challenges of remdesivir for the treatment of coronavirus disease 2019 (COVID-19).

Ejemplares similares